StreetAlpha.app
Home › Stocks › XLO

Xilio Therapeutics, Inc. (XLO)

Members
LATEST PRICE

Xilio Therapeutics develops masked immunotherapy treatments that activate inside tumors to treat cancer. XLO reports earnings on Thu, Nov 12, 2026.

Prices, price targets and earnings estimates for XLO are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is XLO in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 12
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated XLO in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for XLOThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
Raymond JamesInitiated
Oct 21Buy
DateFirmActionRatingPrice target
Oct 21Raymond JamesInitiatedBuy
Loading…

Seasonality

How XLO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in XLO in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XLO is in one of them and how their past XLO trades turned out.

See how it works→ View all auto pilots→
XLO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XLO in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Xilio Therapeutics

Xilio Therapeutics is a biotechnology company that discovers and develops cancer immunotherapies designed to stay inactive until they reach tumors. Enzymes found in tumors remove the mask, which aims to limit activity in healthy tissue. Its pipeline includes a masked IL-2 fusion protein and masked T cell engagers, and it has partnerships with AbbVie and Gilead. The company is based in Waltham, Massachusetts, and is developing its treatments for patients with cancer.

Headquarters
Waltham, MA
Summary based on the company’s 2026 annual report (10-K) ↗